Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
LY3192767 · 1 trial · 1 indication
A summary of SAEs and other non-serious adverse events (AEs), regardless of causality, will be reported in the Reported Adverse Events module
| Arm | Type | Description |
|---|---|---|
| LY3192767 (Part A) | EXPERIMENTAL | Escalating doses of LY3192767 administered subcutaneously (SC). |
| Placebo (Part A) | PLACEBO_COMPARATOR | Placebo matching LY3192767 administered subcutaneously (SC). |
| LY3192767 (Part B) | EXPERIMENTAL | LY3192767 administered as a SC injection in one of three study periods. |
| Basal Insulin Peglispro (Part B) | ACTIVE_COMPARATOR | Basal insulin peglispro administered as a SC injection in one of three study periods. |
| Insulin Glargine (Part B) | ACTIVE_COMPARATOR | Insulin glargine administered as a SC injection in one of three study periods. |
| Name | Type | Description |
|---|---|---|
| LY3192767 | DRUG | Administered SC. |
| Basal Insulin Peglispro | DRUG | Administered SC. |
| Insulin Glargine | DRUG | Administered SC. |
| Placebo | DRUG | Administered SC. |
Inclusion Criteria: * Are overtly healthy males or females, as determined by medical history and physical examination * Have a body mass index (BMI) of \>18.5 and \<30.0 kilogram per square meter (kg/m²), inclusive Exclusion Criteria: * Are currently enrolled in a clinical trial involving an inve...
LY3192767 is an investigational small molecule developed by Eli Lilly and Company. It has been studied in a Phase 1 clinical trial in healthy participants, and no therapeutic indication has been disclosed. It is not an approved medicine and remains in early clinical development.
LY3192767 is made and developed by Eli Lilly and Company, which trades on the New York Stock Exchange under the ticker LLY. Lilly sponsored the Phase 1 study of the compound conducted in Germany.
LY3192767 is in Phase 1 development. Its only recorded clinical trial, NCT03025009, was a Phase 1 study that has been completed. The compound has not advanced beyond Phase 1 based on the available development record.
No. LY3192767 is an investigational drug and is not approved by the FDA. It has completed a single Phase 1 trial in healthy volunteers and has no disclosed indication, so it remains in early clinical development.
LY3192767 has been evaluated in one clinical trial, NCT03025009, titled A Study of LY3192767 in Healthy Participants. The Phase 1 trial enrolled 57 healthy volunteers in Germany, was randomized, double-blind, and placebo-controlled, and is now completed.